FDA: No Indication Contaminated Cough Syrups Have Entered US

France Nouvelles Nouvelles

FDA: No Indication Contaminated Cough Syrups Have Entered US
France Dernières Nouvelles,France Actualités
  • 📰 Medscape
  • ⏱ Reading Time:
  • 49 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 55%

FDA says no indication contaminated cough syrups have entered US supply chain. FDA coughsyrup MedTwitter

March 06, 2023

- The U.S. Food and Drug Administration said on Friday there was no indication that contaminated cough and paracetamol syrups that caused deaths of children in Gambia last year have entered the U.S. drug supply chain. This comes after an investigation led by the U.S. Center for Disease Control and Prevention and Gambian scientists reported on Thursday that these medicines contaminated with toxic levels of diethylene and ethylene glycol led to acute kidney injury among 78 children in Gambia.

"We will continue to monitor the situation and keep the public and health care professionals updated of any changes in status to the U.S. market," Patrizia Cavazzoni, director for FDA's Center for Drug Evaluation and Research, said in a tweet. In October, the World Health Organization sent out an alert saying four cough syrups containing toxic levels of diethylene and ethylene glycol made by India's Maiden Pharmaceuticals Ltd should be withdrawn.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Medscape /  🏆 386. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

FDA will review Eisai and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early JulyFDA will review Eisai and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early JulyFDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
Lire la suite »

Colorado pharmacies caught in the middle of abortion battle after FDA decisionColorado pharmacies caught in the middle of abortion battle after FDA decisionPharmacy chains in Colorado are caught in the middle of the abortion battle after the Food and Drug Administration expanded access to abortion pills earlier this year.
Lire la suite »

Drug shipments to U.S. hold cheap generic Viagra, not opioids feared by FDADrug shipments to U.S. hold cheap generic Viagra, not opioids feared by FDAThe FDA's data from recent years on its seizure of packages containing drugs coming through international mail provides scant evidence that a significant number of opioids enter this way.
Lire la suite »

Eisai, Biogen say FDA grants priority review for Alzheimer's drug LecanemabEisai, Biogen say FDA grants priority review for Alzheimer's drug LecanemabJapanese drugmaker Eisai Co Ltd and its U.S. partner Biogen Inc said on Monday that the U.S. Food and Drug Administration granted priority review for traditional approval of their Alzheimer's treatment Lecanemab.
Lire la suite »

Food fight: FDA is redefining ‘healthy’ and food industry is pushing backFood fight: FDA is redefining ‘healthy’ and food industry is pushing backLess saturated fat, less sodium, less added sugar -- manufacturers say almost no packaged foods would qualify under the agency’s new rules
Lire la suite »

In the mail?: Pro-life, pro-choice advocates turn attention to FDA’s abortion pill planIn the mail?: Pro-life, pro-choice advocates turn attention to FDA’s abortion pill planThe next battleground on abortion lies at the post office — over a 150-year-old anti-vice law that some legal experts say expressly bars the mailing of abortion pills.
Lire la suite »



Render Time: 2025-03-06 16:11:31